QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 taysha-gene-announces-results-from-supplemental-data-analysis-from-part-a-of-reveal-phase-12-adultadolescent-and-pediatric-trials-evaluating-tsha-102-in-females-with-rett-syndrome-at-cns-annual-meeting

Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥...

 baird-maintains-outperform-on-taysha-gene-therapies-raises-price-target-to-12

Baird analyst Jack Allen maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $...

 taysha-gene-therapies-canaan-ondas-holdings-and-other-big-stocks-moving-higher-on-thursday

U.S. stocks were mixed, with the Dow Jones index falling more than 50 points on Thursday.

 needham-maintains-buy-on-taysha-gene-therapies-raises-price-target-to-10

Needham analyst Gil Blum maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target from $8 to $10.

 fda-grants-breakthrough-therapy-designation-to-taysha-gene-therapies-tsha-102-for-rett-syndrome-on-track-to-begin-patient-enrollment-in-q4-2025

Breakthrough Therapy designation granted based on FDA's review of available clinical evidence of safety and efficacy from a...

 wells-fargo-maintains-overweight-on-taysha-gene-therapies-raises-price-target-to-8

Wells Fargo analyst Yanan Zhu maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Overweight and raises the price target fr...

 canaccord-genuity-maintains-buy-on-taysha-gene-therapies-raises-price-target-to-14

Canaccord Genuity analyst Whitney Ijem maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target ...

 chardan-capital-maintains-buy-on-taysha-gene-therapies-raises-price-target-to-10

Chardan Capital analyst Geulah Livshits maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and raises the price target...

 taysha-gene-therapies-q2-eps-009-misses-008-estimate-sales-1986m-beat-1765m-estimate

Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate ...

 b-of-a-securities-initiates-coverage-on-taysha-gene-therapies-with-buy-rating-announces-price-target-of-8

B of A Securities analyst Tazeen Ahmad initiates coverage on Taysha Gene Therapies (NASDAQ:TSHA) with a Buy rating and annou...

 needham-reiterates-buy-on-taysha-gene-therapies-maintains-8-price-target

Needham analyst Gil Blum reiterates Taysha Gene Therapies (NASDAQ:TSHA) with a Buy and maintains $8 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION